End-stage Renal Disease Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The End-stage Renal Disease Market is Segmented by Treatment (Kidney Transplantation and Dialysis), Diagnosis (Blood Test, Urine Test, Imaging Test, and Other Diagnoses), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.

End-stage Renal Disease Market Size

End-stage Renal Disease Market Summary
share button
Study Period 2019-2027
Base Year For Estimation 2022
CAGR 10.00 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration High

Major Players

End-stage Renal Disease Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

End-stage Renal Disease Market Analysis

The end-stage renal disease market is expected to witness a CAGR of around 10% during the forecast period.

The COVID-19 pandemic forced unprecedented changes in the daily life of people. Many patients were under lockdown during this time, and the nephrology community was forced to adapt quickly to this new reality. Patients on dialysis were at high risk of COVID-19 exposure due to the widespread use of public transportation and densely packed clinical spaces. For instance, according to an article published by Karger in June 2022, chronic hemodialysis (HD) patients were considered at high risk of severe COVID-19 with an increased risk of death, and the constraints during the pandemic had an impact on the dialysis delivery to COVID-free hemodialysis patients. Thus the COVID-19 pandemic had a significant effect on the current market initially. However, post-pandemic, the market studied is expected to grow significantly during the forecast period.

The end-stage renal disease market is driven by the increasing number of patients suffering from chronic kidney disease. According to the article published by PubMed Central in April 2022, approximately 10% of the global population suffers from chronic kidney disease, and millions die each year. According to the same article, the rate of patients with chronic kidney disease is increasing.

Another factor is the introduction of technologically advanced products, like low-maintenance dialysis equipment and artificial kidney. In March 2021, Baxter International Inc. announced the United States FDA clearance of its next-generation Artificial Kidney 98 dialysis machine, designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. This indicated that companies are taking initiatives to establish a strong footprint and launch technologically advanced products in the market.

Additionally, there is a higher prevalence rate for diabetes, which leads to cause end-stage renal disease in the long run, which may drive the market growth. According to the International Diabetes Federation, in 2021, around 537 million adults (20-79 years) were living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 by 2045. Diabetes is one of the leading causes of kidney failure, which is likely to drive the market's growth over the forecast period.

Therefore, owing to the factors mentioned above, such as the rising prevalence of diabetes and the introduction of technologically advanced products, the market studied is anticipated to witness growth over the analysis period. However, the delay in diagnosing chronic kidney disease may restrain the market growth over the forecast period.

End-stage Renal Disease Market Trends

This section covers the major market trends shaping the End-stage Renal Disease Market according to our research experts:

Dialysis Segment by Treatment is Expected to Witness a Significant Growth over the Forecast Period

Dialysis is a procedure that removes waste products from the blood, such as urea and creatinine, as a result of impaired kidney function. It is frequently required for persons with chronic renal failure. The blood is cleansed, and extra fluid and toxins are eliminated during this operation.

Moreover, the demand for dialysis is expected to increase as the incidence of end-stage renal disease increases worldwide. The prevalence of end-stage renal disease (ESRD) is high and growing at a significant rate. According to the article published by the National Institute of Health (NIH) in 2021, nearly 786,000 people in the United States were living with ESRD, with 71% on dialysis and 29% with a kidney transplant. Meanwhile, the number of patients who initiated peritoneal dialysis and received a preemptive transplant reached an all-time high of 18,631. According to the American Society of Nephrology, funding for dialysis is rising in the United States.

The end-stage renal disease market is growing as the population increases globally, thus, raising funding for better dialysis products and services. For instance, on July 1, 2021, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule for the Prospective Payment System (PPS) for renal dialysis services. Under the ESRD PPS for 2022, Medicare is expected to pay USD 8.9 billion to approximately 7,700 ESRD facilities for furnishing renal dialysis services.

On the other hand, factors like the high prevalence of diabetics, hypertension, rising incidences of kidney failures, lack of kidney donors for transplantation, tedious kidney transplant procedure, and increasing demand for home peritoneal dialysis treatment drive the segmental growth over the forecast period.

End-stage Renal Disease Market - Estimated Research Funding for Kidney Diseases (in Million), United States, 2021-2023

Asia-Pacific is is Expected to Witness a High Growth over the Forecast Period

Asia-Pacific is expected to witness high growth in end-stage renal disease due to the presence of high disposable income and the high acceptance rate of technologically improved products. Moreover, high blood pressure and diabetes cases in the region may contribute to the market growth. According to the data from the International Diabetes Federation in December 2021, an estimated 90 million adults were living with diabetes in the South-East Asia (SEA) region in 2021. This is estimated to increase to 113 million by 2030 and 152 million by 2045. Moreover, according to the same source, 46 million adults living with diabetes in the IDF SEA Region are undiagnosed, accounting for 51% of the total number of adults living with diabetes in the region.

Additionally, growing patient affordability, an aging population, lifestyle stress, a broad population base, and improving diagnosis quality are expected to fuel market growth. According to a report published by the national health portal of the Indian Government in July 2022, it is estimated that every year about 2.2 lakh new patients of end-stage renal disease (ESRD) are increasing, resulting in demand for 3.4 crore dialysis every year. Approximately 4,950 dialysis centers were available, largely in the private sector in India. The presence of a large number of dialysis centers in this region and a rise in the number of patients with chronic renal and kidney diseases are expected to boost the market growth.

End-stage Renal Disease Market - Growth Rate by Region

End-stage Renal Disease Industry Overview

The market studied is fragmented due to the presence of many major market players. Market players adopt the strategies, such as organic growth strategies (treatment type launches, treatment type approvals) and others (such as patents and events), which are prioritized by corporations with inorganic growth strategies, like acquisitions, partnerships, and collaborations. Some market players are Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc., Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical, Nikkiso Co., etc.

End-stage Renal Disease Market Leaders

  1. Nipro Corporation

  2. Fresenius SE & Co. KGaA

  3. Baxter International Inc

  4. Medtronic PLC

  5. B. Braun SE

*Disclaimer: Major Players sorted in no particular order

End-stage Renal Disease Market Concentration

End-stage Renal Disease Market News

  • April 2022- Fresenius Medical Care announced that the United States FDA approved the Versi PD Cycler System. It is a next-generation portable automated peritoneal dialysis system approved in North America.
  • March 2022- The Health Minister launched a Hemodialysis unit at New Souillac in the presence of the World Health Representative to mark world kidney day in Mauritius. This new unit comprises 22 hemodialysis machines that can accommodate around 150 patients and aims at further decentralizing the treatment of patients suffering from Kidney disease.

End-stage Renal Disease Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Number of Patient Suffering from Chronic Kidney Disease

      2. 4.2.2 Introduction of Technologically Advanced Products

      3. 4.2.3 Rising Prevalence of Diabetes and Hypertension

    3. 4.3 Market Restraints

      1. 4.3.1 Delay in Diagnosis of the Chronic Kidney Disease

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value in USD million)

    1. 5.1 By Treatment

      1. 5.1.1 Kidney Transplantation

      2. 5.1.2 Dialysis

    2. 5.2 By Diagnosis

      1. 5.2.1 Blood Test

      2. 5.2.2 Urine Test

      3. 5.2.3 Imaging Test

      4. 5.2.4 Other Diagnoses

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Nipro Corporation

      2. 6.1.2 Fresenius SE & Co. KGaA

      3. 6.1.3 Baxter International Inc.

      4. 6.1.4 Medtronic PLC

      5. 6.1.5 B. Braun SE

      6. 6.1.6 Asahi Kasei Medical Co. Ltd

      7. 6.1.7 Cantel Medical (STERIS)

      8. 6.1.8 Nikkiso Co. Ltd

      9. 6.1.9 Becton, Dickinson and Company

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers - Business Overview, Financials, Products and Strategies and Recent Developments

End-stage Renal Disease Industry Segmentation

End-stage renal failure, also known as an end-stage renal disease (ESRD), is the final, permanent stage of chronic kidney disease, where kidneys can no longer function independently. 

The End-stage Renal Disease Market is Segmented by Treatment (Kidney Transplantation and Dialysis), Diagnosis (Blood Test, Urine Test, Imaging Test, and Other Diagnoses), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.

By Treatment
Kidney Transplantation
Dialysis
By Diagnosis
Blood Test
Urine Test
Imaging Test
Other Diagnoses
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

You can also purchase parts of this report. Do you want to check out a section wise price list?

End-stage Renal Disease Market Research FAQs

The End-stage Renal Disease Market is projected to register a CAGR of 10% during the forecast period (2023-2027).

Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc, Medtronic PLC and B. Braun SE are the major companies operating in the End-stage Renal Disease Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2027).

In 2023, the North America accounts for the largest market share in the End-stage Renal Disease Market.

End-stage Renal Disease Industry Report

Statistics for the 2023 End-stage Renal Disease market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. End-stage Renal Disease analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!